Discount Link Metabolomics Market Research

Table of Contents

1 Introduction (Page No. - 16)
    1.1 Objectives of the Study 
    1.2 Market Definition 
    1.3 Market Scope 
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency 
    1.5 Limitations 
    1.6 Stakeholders

2 Research Methodology (Page No. - 20)
    2.1 Research Methodology 
    2.2 Secondary and Primary Research Methodology 
           2.2.1 Secondary Research
                     2.2.1.1 Key Data From Secondary Sources
           2.2.2 Primary Research
                     2.2.2.1 Key Data From Primary Sources
                     2.2.2.2 Key Insights From Primary Sources
                     2.2.2.3 Key Industry Insights
    2.3 Market Size Estimation Methodology 
    2.4 Market Forecast Methodology 
    2.5 Market Data Validation and Triangulation 
    2.6 Assumptions for the Study

3 Executive Summary (Page No. - 30)
    3.1 Introduction 
    3.2 Conclusion

4 Premium Insights (Page No. - 36)
    4.1 Humanized Mouse Model: Market Overview 
    4.2 Regional Analysis: Global Market, By End User 
    4.3 Global Market, By Application, 2016 vs 2021 
    4.4 Regional Snapshot: Global Market

5 Market Overview (Page No. - 39)
    5.1 Introduction 
    5.2 Market Dynamics 
           5.2.1 Drivers
                     5.2.1.1 Surge in the Number of Research Activities Involving Humanized Mouse Models
                                         5.2.1.1.1 Mice Models for Immunodeficiency Disorders
                                         5.2.1.1.2 Mice Models for Cancer
                                         5.2.1.1.3 Mice Models for Rare Diseases
                     5.2.1.2 Growing Adoption of Personalized Medicine to Fuel the Demand for Personalized Mice Models
                     5.2.1.3 Continuous Support in the Form of Investments and Grants From the Government and Private Sectors
                                         5.2.1.3.1 Funding/Grants By the National Institutes of Health (NIH)
                                         5.2.1.3.2 Funding/Grants Received From Other Government Bodies
                     5.2.1.4 Increase in R&D Activities Carried Out By Pharmaceutical and Biotechnology Companies
           5.2.2 Restraints
                     5.2.2.1 Regulations & Laws Formulated for Ethical Use of Animals
                                         5.2.2.1.1 The Animal Welfare Act (AWA)
                                         5.2.2.1.2 Public Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals
                     5.2.2.2 Increased Use of Rat Models
           5.2.3 Opportunities
                     5.2.3.1 Increased Production of Monoclonal Antibodies
           5.2.4 Challenges
                     5.2.4.1 Advances in Zebrafish Model Development
                     5.2.4.2 Alternative Methods of Animal Testing
                     5.2.4.3 Limitations of Humanized Mouse Models

6 Clinical Trials & Research Studies Assessment (Page No. - 49)
    6.1 Introduction 
    6.2 Clinical Trials 
    6.3 Research Studies

7 Humanized Mouse Model Market, By Type (Page No. - 56)
    7.1 Introduction 
    7.2 Genetic Humanized Mouse Model 
    7.3 Cell-Based Humanized Mouse Model 
           7.3.1 CD34 Humanized Mouse Model (Hu-CD34)
           7.3.2 PBMC Humanized Mouse Model
           7.3.3 BLT Humanized Mouse Model

8 Humanized Mouse Model Market, By Application (Page No. - 66)
    8.1 Introduction 
    8.2 Oncology 
           8.2.1 Agreements/Collaborations to Strengthen Cancer Research
           8.2.2 Continuous Grants/Funds to Support Cancer Research Studies
    8.3 Immunology and Infectious Diseases 
    8.4 Neurosciences 
           8.4.1 Grants/Funds for Neurological Research
    8.5 Toxicology 
    8.6 Hematopoiesis 
    8.7 Other Applications 
           8.7.1 Increasing Funding for Rare Disease Research

9 Humanized Mouse Model Market, By End User (Page No. - 78)
    9.1 Introduction 
    9.2 Pharmaceutical & Biotechnology Companies 
    9.3 Contract Research Organizations 
    9.4 Academic & Research Institutions

10 Global Market, By Region (Page No. - 85)
     10.1 Introduction 
     10.2 North America 
               10.2.1 U.S.
                           10.2.1.1 Availability of Support for Research in the U.S.
                           10.2.1.2 Preclinical Activities By Cros and Pharmaceutical R&D
                           10.2.1.3 Conferences and Other Events Contributing to the Spread of Innovation and Awareness
                           10.2.1.4 Growing Monoclonal Antibody Production
                           10.2.1.5 Development of Biosimilars Boosting the Demand for Preclinical Services
               10.2.2 Canada
                           10.2.2.1 Growing Stem Cell Research in Canada
                           10.2.2.2 Government Support for Development of Protein Drugs
     10.3 Europe 
               10.3.1 Launch of Pro-Test Deutschland in Germany
               10.3.2 Flourishing Biotechnology Industry in Germany
               10.3.3 Emphasis on Quality Research Results in the U.K.
               10.3.4 Increase in Cell Therapy Preclinical Research in the U.K.
               10.3.5 Funding for Rare Disease Projects in France
               10.3.6 Growth in Biotech and Pharma Sector of Italy
               10.3.7 Growing Investments in Research By Sweden & Denmark
     10.4 Asia-Pacific 
               10.4.1 China: Strong Research Expenditure, Well-Structured Cro Industry
               10.4.2 Mandatory Animal Testing for All Pharmaceutical Drugs and Cosmetics in China
               10.4.3 Rising Focus on Personalized Medicine in China
               10.4.4 Increasing Investments From Government and Private Sectors in China’s Life Sciences Sector
               10.4.5 Japan: Government Support for Research, Growth in Biomedical and Medical Research
               10.4.6 Research in Regenerative Medicine in Japan
               10.4.7 Growth of the Pharmaceutical Industry in India
               10.4.8 Development of Bio-Clusters to Boost India’s Biotechnology Sector
               10.4.9 Infrastructural Limitations in India: A Key Hindrance for Market Growth
               10.4.10 Ongoing Biomedical Research Activities in Australia
               10.4.11 Growth in Translational and Biomedical Research in Singapore
               10.4.12 Increase in Animal Research in Malaysia
               10.4.13 Rising Pharmaceutical and Biotechnology R&D Activities in Korea
     10.5 Rest of the World 
               10.5.1 Brazil: Growth in the Pharmaceutical, Biotechnology, and Research Industries
               10.5.2 Favorable Business Environment for Pharmaceutical and Biotechnology Industries in Saudi Arabia and the UAE
               10.5.3 Increasing Investments in Mexico

11 Competitive Landscape (Page No. - 119)
     11.1 Overview 
     11.2 Market Share Analysis 
               11.2.1 Introduction
               11.2.2 Cell-Based Humanized Mouse Model Market
                           11.2.2.1 The Jackson Laboratory (U.S.)
                           11.2.2.2 Taconic Biosciences, Inc. (U.S.)
               11.2.3 Genetic Humanized Mouse Model Market
                           11.2.3.1 Horizon Discovery Group PLC  (U.K.)
                           11.2.3.2 Taconic Biosciences, Inc. (U.S.)
     11.3 Competitive Situation and Trends 
     11.4 Agreements, Collaborations, Contracts, Alliances, and Partnerships 
     11.5 Grant/Fund 
     11.6 Product Launches 
     11.7 Expansions 
     11.8 Acquisitions 
     11.9 Other Strategies

12 Company Profiles (Page No. - 132)
(Overview, Products and Services, Financials, Strategy & Development)*
     12.1 Introduction 
     12.2 The Jackson Laboratory 
     12.3 Taconic Biosciences, Inc. 
     12.4 Horizon Discovery Group PLC  
     12.5 Genoway S.A. 
     12.6 Harbour Antibodies Bv (A Subsidiary of Harbour Biomed) 
     12.7 Humurine Technologies 
     12.8 Vitalstar Biotechnology Co., Ltd. 
     12.9 Ingenious Targeting Laboratory 
     12.10 Axenis S.A.S 
     12.11 Trans Genic, Inc. 
     12.12 Champions Oncology, Inc. 
     12.13 Crown Bioscience, Inc.

*Details on Overview, Products and Services, Financials, Strategy & Development Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. - 162)
     13.1 Discussion Guide 
     13.2 Other Developments (2013–2016) 
               13.2.1 the Jackson Laboratory
               13.2.2 Taconic Biosciences, Inc.
               13.2.3 Horizon Discovery Group PLC
               13.2.4 Genoway S.A.
               13.2.5 Ingenious Targeting Laboratory
               13.2.6 Trans Genic, Inc.
               13.2.7 Champions Oncology, Inc.
               13.2.8 Crown Bioscience, Inc.
     13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal 
     13.4 Introducing RT: Real-Time Market Intelligence 
     13.5 Available Customizations 
     13.6 Related Reports 
     13.7 Author Details

List of Tables (69 Tables)

Table 1 Indicative List of Ongoing Clinical Trials Conducted on Humanized Mice Models
Table 2 Indicative List of Research Studies Conducted on Humanized Mice Models (2013–2016)
Table 3 Global Humanized Mouse Model Market Size, By Type, 2014–2021 (USD Million)
Table 4 Genetic Market Size, By Region, 2014–2021 (USD Million)
Table 5 Global Cell-Based Market Size, By Type, 2014–2021 (USD Million)
Table 6 Cell-Based Market Size, By Region, 2014–2021 (USD Million)
Table 7 North America: Cell-Based Market Size, By Country, 2014–2021 (USD Million)
Table 8 CD34 Humanized Mouse Model Market Size, By Region, 2014–2021 (USD Million)
Table 9 North America: CD34 Humanized Mouse Model Market Size, By Country, 2014–2021 (USD Million)
Table 10 PBMC Humanized Mouse Model Market Size, By Region, 2014–2021 (USD Million)
Table 11 North America: PBMC Humanized Mouse Model Market Size, By Country, 2014–2021 (USD Million)
Table 12 Recent HIV Studies Using Humanized Mouse Model
Table 13 BLT Market Size, By Region, 2014–2021 (USD Thousand)
Table 14 North America: BLT Market Size, By Country, 2014–2021 (USD Thousand)
Table 15 Global Market, By Application, 2014–2021 (USD Million)
Table 16 Indicative List of Recent Cancer Research Studies Using Humanized Mice Models
Table 17 Market for Oncology, By Region, 2014–2021 (USD Million)
Table 18 North America: Market Size for Oncology, By Country, 2014–2021 (USD Million)
Table 19 Market Size for Immunology and Infectious Diseases, By Region, 2014–2021 (USD Million)
Table 20 North America: Market Size for Immunology and Infectious Diseases, By Country, 2014–2021 (USD Million)
Table 21 Market Size for Neurosciences, By Region, 2014-2021 (USD Million)
Table 22 North America: Market Size for Neurosciences, By Country, 2014–2021 (USD Million)
Table 23 Market Size for Toxicology, By Region, 2014-2021 (USD Million)
Table 24 North America: Market Size for Toxicology, By Country, 2014–2021 (USD Million)
Table 25 Market Size for Hematopoiesis, By Region, 2014-2021 (USD Million)
Table 26 North America: Market Size for Hematopoiesis, By Country, 2014–2021 (USD Million)
Table 27 Market Size for Other Applications, By Region, 2014-2021 (USD Million)
Table 28 North America: Market Size for Other Applications, By Country, 2014–2021 (USD Million)
Table 29 Global Market, By End User, 2014–2021 (USD Million)
Table 30 Market Size for Pharmaceutical & Biotechnology Companies, By Region, 2014–2021 (USD Million)
Table 31 North America: Market Size for Pharmaceutical & Biotechnology Companies, By Country, 2014–2021 (USD Million)
Table 32 Market Size for Contract Research Organizations, By Region, 2014–2021 (USD Million)
Table 33 North America: Market Size for Contract Research Organizations, By Country, 2014–2021 (USD Million)
Table 34 Market Size for Academic & Research Institutions, By Region, 2014–2021 (USD Million)
Table 35 North America: Market Size for Academic & Research Institutions, By Country, 2014–2021 (USD Million)
Table 36 Market, By Region, 2014–2021 (USD Million)
Table 37 North America: Market, By Country, 2014–2021 (USD Million)
Table 38 North America: Market, By Type, 2014–2021 (USD Million)
Table 39 North America: Cell-Based Market Size, By Type, 2014–2021 (USD Million)
Table 40 North America: Market, By Application, 2014–2021 (USD Million)
Table 41 North America: Market, By End User, 2014–2021 (USD Million)
Table 42 Nih Funding for Projects Related to Animal Models
Table 43 Recent Events Related to the Animal Model Market
Table 44 U.S.: Market, By Type, 2014–2021 (USD Million)
Table 45 U.S.: Cell-Based Humanized Mouse Model Market Size, By Type, 2014–2021 (USD Million)
Table 46 U.S.: Market, By Application, 2014–2021 (USD Million)
Table 47 U.S.: Market, By End User, 2014–2021 (USD Million)
Table 48 Canada: Market, By Type, 2014–2021 (USD Million)
Table 49 Canada: Cell-Based Humanized Mouse Model Market Size, By Type, 2014–2021 (USD Thousand)
Table 50 Canada: Market, By Application, 2014–2021 (USD Thousand)
Table 51 Canada: Market, By End User, 2014–2021 (USD Million)
Table 52 Europe:Market, By Type, 2014–2021 (USD Million)
Table 53 Europe: Cell-Based Humanized Mouse Model Market Size, By Type, 2014–2021 (USD Million)
Table 54 Europe: Market, By Application, 2014–2021 (USD Million)
Table 55 Europe: Market, By End User, 2014–2021 (USD Million)
Table 56 Asia-Pacific: Market, By Type, 2014–2021 (USD Million)
Table 57 Asia-Pacific: Cell-Based Market Size, By Type, 2014–2021 (USD Thousand)
Table 58 Asia-Pacific: Market, By Application, 2014–2021 (USD Thousand)
Table 59 Asia-Pacific: Market, By End User, 2014–2021 (USD Million)
Table 60 RoW: Market, By Type, 2014–2021 (USD Million)
Table 61 RoW: Cell-Based Humanized Mouse Model Market Size, By Type, 2014–2021 (USD Thousand)
Table 62 RoW: Market, By Application, 2014–2021 (USD Thousand)
Table 63 RoW:  Market, By End User, 2014–2021 (USD Million)
Table 64 Agreements, Collaborations, Contracts, Alliances, and Partnerships, 2013–2016
Table 65 Grant/Fund, 2013–2016
Table 66 Product Launches, 2013–2016
Table 67 Expansions, 2013–2016
Table 68 Acquisitions, 2013–2016
Table 69 Other Strategies, 2013–2016
 
 
List of Figures (47 Figures)
 
Figure 1 Global Humanized Mouse Model Market: Research Methodology
Figure 2 Sampling Frame: Primary Research
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Market Size Estimation Methodology: Bottom-Up Approach
Figure 5 Market Size Estimation Methodology: Top-Down Approach
Figure 6 Research Design
Figure 7 Data Triangulation Methodology
Figure 8 Global Market, By Application (2016)
Figure 9 Global Market, By Type
Figure 10 Global Cell-Based Humanized Mouse Model Market, By Type
Figure 11 Global Market, By End User
Figure 12 Asia-Pacific to Witness Highest Growth During the Forecast Period
Figure 13 Increasing R&D Activities, Investments, and Grants to Drive Growth in the Global Humanized Mouse Model Market
Figure 14 North America to Dominate the Global Humanized Mouse Model Market in 2016
Figure 15 Oncology to Form the Largest Application Segment in the Global Humanized Mouse Model Market
Figure 16 Asia-Pacific to Register the Highest Market Growth From 2016 to 2021
Figure 17 Drivers, Restraints, Opportunities, and Challenges
Figure 18 U.S.: Clinical Trials Using Humanized Mice Models, By Indication (2013–2023)
Figure 19 U.S.: Clinical Trials Using Humanized Mice Models, By Completion
Figure 20 U.S.: Clinical Trials Using Humanized Mice Models, By Phase (2013–2023)
Figure 21 U.S.: Research Studies Using Humanized Mice Models, By Indication (2012–2016)
Figure 22 Genetic Humanized Mouse Model to Account for the Largest Market Share in 2016
Figure 23 CD34 Humanized Mouse Model to Grow at the Highest CAGR Between 2016 and 2021
Figure 24 Oncology Segment to Dominate the Humanized Mouse Model Market in 2016
Figure 25 Pharmaceutical & Biotechnology Companies to Dominate the Humanized Mouse Model Market in 2016
Figure 26 North America Dominates the Market for Humanized Mouse Models
Figure 27 North America: Humanized Mouse Model Market Snapshot
Figure 28 Europe: Market Snapshot
Figure 29 Increase in Cell Therapy Preclinical Studies in the U.K., 2013-2016
Figure 30 Asia-Pacific: Market Snapshot
Figure 31 Rest of the World: Market Snapshot
Figure 32 Key Developments in the Humanized Mouse Model Market, 2013–2016
Figure 33 Market Share Analysis for Cell-Based Humanized Mouse Model, By Key Player, 2015
Figure 34 Market Share Analysis for Genetic Humanized Mouse Model, By Key Player, 2015
Figure 35 Agreements, Collaborations, Contracts, Alliances, and Partnerships Was the Key Growth Strategy Adopted By Market Players
Figure 36 Agreements, Collaborations, Alliances, Contracts, and Partnerships, By Company (2013–2016)
Figure 37 Grant/Fund, By Company (2013–2016)
Figure 38 Product Launches, By Company (2013–2016)
Figure 39 Expansions, By Company (2013–2016)
Figure 40 Acquisitions, By Company (2013–2016)
Figure 41 Other Strategies, By Company (2013–2016)
Figure 42 Product Mix of the Top 3 Players in the Humanized Mouse Models Market
Figure 43 The Jackson Laboratory: Company Snapshot (2015)
Figure 44 Horizon Discovery Group PLC: Company Snapshot (2015)
Figure 45 Genoway S.A.: Company Snapshot (2015)
Figure 46 Trans Genic, Inc.: Company Snapshot (2015)
Figure 47 Champions Oncology, Inc.: Company Snapshot (2015)